Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Polypeptide conjugates of D-penicillamine and idarubicin for anticancer therapy.

Wadhwa S, Mumper RJ.

J Control Release. 2012 Mar 10;158(2):215-23. doi: 10.1016/j.jconrel.2011.10.027. Epub 2011 Oct 29.

PMID:
22063001
2.
3.
4.

Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer.

Liu J, Liu J, Chu L, Wang Y, Duan Y, Feng L, Yang C, Wang L, Kong D.

Int J Nanomedicine. 2010 Dec 22;6:59-69. doi: 10.2147/IJN.S14601.

5.

Formulation and optimization of idarubicin thermosensitive liposomes provides ultrafast triggered release at mild hyperthermia and improves tumor response.

Lu T, Lokerse WJM, Seynhaeve ALB, Koning GA, Ten Hagen TLM.

J Control Release. 2015 Dec 28;220(Pt A):425-437. doi: 10.1016/j.jconrel.2015.10.056. Epub 2015 Nov 3.

PMID:
26541464
6.

Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.

Tsuruo T, Oh-Hara T, Sudo Y, Naito M.

Anticancer Res. 1993 Mar-Apr;13(2):357-61.

PMID:
8517647
7.

Poly (γ, L-glutamic acid)-cisplatin bioconjugate exhibits potent antitumor activity with low toxicity: a comparative study with clinically used platinum derivatives.

Feng Z, Lai Y, Ye H, Huang J, Xi XG, Wu Z.

Cancer Sci. 2010 Nov;101(11):2476-82. doi: 10.1111/j.1349-7006.2010.01708.x. Epub 2010 Sep 1.

8.

Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice.

Zou Y, Wu QP, Tansey W, Chow D, Hung MC, Charnsangavej C, Wallace S, Li C.

Int J Oncol. 2001 Feb;18(2):331-6.

PMID:
11172600
9.

Methoxypoly(ethylene glycol)-block-poly(L-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers.

Song W, Li M, Tang Z, Li Q, Yang Y, Liu H, Duan T, Hong H, Chen X.

Macromol Biosci. 2012 Nov;12(11):1514-23. doi: 10.1002/mabi.201200145. Epub 2012 Oct 15.

PMID:
23070837
10.

Enhanced intracellular delivery of the reactive oxygen species (ROS)-generating copper chelator D-penicillamine via a novel gelatin--D-penicillamine conjugate.

Gupte A, Wadhwa S, Mumper RJ.

Bioconjug Chem. 2008 Jul;19(7):1382-8. doi: 10.1021/bc800042s. Epub 2008 Jun 21.

PMID:
18570451
11.

The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.

Majlessipour F, Avramis IA, Kwock R, Weinberg KI, Avrami VI.

Anticancer Res. 2002 May-Jun;22(3):1361-8.

PMID:
12168812
12.

Effects of polyphyllin I on growth inhibition of human non-small lung cancer cells and in xenograft.

Kong M, Fan J, Dong A, Cheng H, Xu R.

Acta Biochim Biophys Sin (Shanghai). 2010 Nov;42(11):827-33. doi: 10.1093/abbs/gmq091.

PMID:
20978038
13.

High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.

Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.

Cancer Chemother Pharmacol. 2007 May;59(6):771-9. Epub 2007 Jan 26.

PMID:
17256136
14.

Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicin-monoclonal antibody conjugates.

Smyth MJ, Foster HM, Andrew SM, Teh JG, Krauer K, McKenzie IF, Pietersz GA.

Immunol Cell Biol. 1993 Jun;71 ( Pt 3):167-79.

15.

Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.

Ma P, Dong X, Swadley CL, Gupte A, Leggas M, Ledebur HC, Mumper RJ.

J Biomed Nanotechnol. 2009 Apr;5(2):151-61.

16.
17.

Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma.

Harris SM, Scott JA, Brown JL, Charlton PA, Mistry P.

Anticancer Drugs. 2005 Oct;16(9):945-51.

PMID:
16162971
18.

Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.

Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R.

Clin Cancer Res. 2004 Dec 15;10(24):8641-7.

19.

[Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].

Watanabe A, Kuriyama H, Kiyota T.

Gan To Kagaku Ryoho. 1996 Feb;23(3):291-6. Japanese.

PMID:
8712821
20.

Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.

Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM, Appelt K.

Clin Cancer Res. 1999 Jul;5(7):1905-17.

Supplemental Content

Support Center